Comparing Envoy Medical (NASDAQ:COCH) and Mesa Laboratories (NASDAQ:MLAB)

Envoy Medical (NASDAQ:COCH) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Risk and Volatility

Envoy Medical has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Mesa Laboratories has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Envoy Medical and Mesa Laboratories”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$241,000.00	222.35	-$23.76 million	($1.22)	-0.57
Mesa Laboratories	$247.54 million	2.32	-$1.97 million	$0.64	162.27

Mesa Laboratories has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by company insiders. Comparatively, 4.9% of Mesa Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Envoy Medical and Mesa Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,857.26%	N/A	-256.65%
Mesa Laboratories	1.51%	22.02%	8.86%

Analyst Recommendations

This is a summary of current ratings and target prices for Envoy Medical and Mesa Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1	1	2	0	2.25
Mesa Laboratories	1	2	0	0	1.67

Envoy Medical currently has a consensus target price of $6.00, suggesting a potential upside of 760.83%. Mesa Laboratories has a consensus target price of $94.00, suggesting a potential downside of 9.48%. Given Envoy Medical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Envoy Medical is more favorable than Mesa Laboratories.

Summary

Mesa Laboratories beats Envoy Medical on 8 of the 14 factors compared between the two stocks.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

About Mesa Laboratories

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.